Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14710297 | 0.95 | HSD11B1 (0.40) | HRH3HSD11B1ALDH1A1SMN1; SMN2KCNA3 | |
| SCHEMBL1678709 | 0.85 | HRH3 (0.46) | HRH3HSD11B1LPAR1 | |
| SCHEMBL16477203 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14712065 | 0.83 | HRH3 (0.45) | HRH3HSD11B1LPAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14711330 | 0.82 | HRH3 (0.44) | HRH3HSD11B1LPAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14710596 | 0.80 | OPRM1 (0.42) | HRH3HSD11B1ALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL844453 | 0.79 | OPRM1 (0.53) | HRH3HSD11B1ALDH1A1SMN1; SMN2OPRM1 | |
| SCHEMBL1464894 | 0.79 | CA12 (0.44) | HRH3HSD11B1ALDH1A1SMN1; SMN2KCNA3 | |
| SCHEMBL14712079 | 0.78 | HRH3 (0.49) | HRH3ALDH1A1 | |
| SCHEMBL5641709 | 0.77 | OPRM1 (0.52) | HRH3HSD11B1ALDH1A1SMN1; SMN2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019041340-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | HRH3 140/4885HSD11B1 2652/4885LPAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.